KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cineverse (CNVS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cineverse (CNVS) over the last 17 years, with Q3 2025 value amounting to $2.3 million.

  • Cineverse's Cash & Equivalents fell 382.87% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 382.87%. This contributed to the annual value of $13.9 million for FY2025, which is 16980.84% up from last year.
  • Latest data reveals that Cineverse reported Cash & Equivalents of $2.3 million as of Q3 2025, which was down 382.87% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Cineverse's Cash & Equivalents peaked at $20.2 million during Q4 2021, and registered a low of $2.0 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $8.8 million (2022), whereas its average is $9.3 million.
  • Per our database at Business Quant, Cineverse's Cash & Equivalents crashed by 7182.13% in 2024 and then skyrocketed by 16980.84% in 2025.
  • Quarter analysis of 5 years shows Cineverse's Cash & Equivalents stood at $20.2 million in 2021, then tumbled by 56.46% to $8.8 million in 2022, then crashed by 37.03% to $5.5 million in 2023, then grew by 9.82% to $6.1 million in 2024, then tumbled by 61.6% to $2.3 million in 2025.
  • Its Cash & Equivalents was $2.3 million in Q3 2025, compared to $2.0 million in Q2 2025 and $13.9 million in Q1 2025.